TICKERNERD
Menu
DFTXHealthcare · Biotechnology

DFTX Stock Forecast: Definium Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$42
−3.98% on the day

The 16 Wall Street analysts covering Definium Therapeutics, Inc. hold a median 12-month price target of $59 — +41.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 38 of 100 as at 1 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$5.8B
Ticker Nerd rank
38 / 100
Median analyst target
$59
Analysts covering
16
Total return, dividends reinvested
1W
−2.0%
1M
−5.4%
YTD
+212.1%
1Y
+395.1%
From 52W high
−13.7%
From 52W low
+370.6%
$9
$48
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

DFTX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Definium Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
38 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
100
Value
79
Accruals
58
Volatility
55
Revisions
47
Quality
38
Growth
25
Size
22
Issuance
12

Momentum (100): The shares have been drifting up relative to others.

Issuance (12): The company has been issuing shares or taking on financing, diluting existing holders.

The rank is the raw material. Whether the rules would actually own Definium Therapeutics, Inc. — and when they’d sell — is the membership.

Wall Street

DFTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on DFTX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$20$40$60$80Oct 25Jan 26Apr 26Jul 26DFTXHigh $74Median $59Low $50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says16 analysts
16 Buy0 Hold0 Sell
Low $50Median $59High $74

The green dot is the last close — the median target sits +41.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
27 July 2026Wells FargoInitiatesOverweight$68
24 July 2026Piper SandlerReiteratesOverweight$48 → $73
8 July 2026StifelMaintainsBuy—
8 July 2026StifelMaintainsBuy$30 → $60
30 June 2026Canaccord GenuityMaintainsBuy—
24 June 2026Jones TradingMaintainsBuy—
23 June 2026BairdMaintainsOutperform—
23 June 2026NeedhamMaintainsBuy—
22 June 2026Leerink PartnersMaintainsOutperform—
22 June 2026OppenheimerMaintainsOutperform—
16 June 2026Canaccord GenuityMaintainsBuy—
8 May 2026Piper SandlerMaintainsOverweight—
22 Apr 2026Leerink PartnersMaintainsOutperform—
17 Apr 2026StifelInitiatesBuy—
16 Apr 2026Canaccord GenuityMaintainsBuy—
10 Apr 2026Piper SandlerInitiatesOverweight—
2 Mar 2026HC Wainwright & Co.MaintainsBuy—
24 Feb 2026Wolfe ResearchInitiatesOutperform—
30 Jan 2026JefferiesInitiatesBuy—
23 Jan 2026RBC CapitalMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

DFTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
2
Fundamentals

Definium Therapeutics, Inc. (DFTX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−21.1×

Cheaper than 96% of US stocks

Price / sales
—
Price / book
16.2×

Cheaper than 6% of US stocks

EV / EBITDA
−28.4×

Cheaper than 91% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 35% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−94.7%

Higher than 14% of US stocks

Return on assets
−35.7%

Higher than 12% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

DFTX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
DFTXDefinium Therapeutics, Inc.$5.8B
38
PTCTPTC Therapeutics, Inc.$5.6B
70
LGNDLigand Pharmaceuticals, Inc.$5.7B
75
ORKAOruka Therapeutics, Inc.$5.8B
48
DNTHDianthus Therapeutics, Inc.$5.8B
53
SRRKScholar Rock Holding Corp.$5.4B
28
XENEXenon Pharmaceuticals, Inc.$6.0B
43
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DFTX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest DFTX news & analysis

Wall Street Analysts See a 34.86% Upside in Definium Therapeutics, Inc. (DFTX): Can the Stock Really Move This High?

Zacks Investment Research · 31 July 2026neutral

Zacks Investment Research reported that the average of Wall Street analysts' price targets implies a potential 34.9% upside in Definium Therapeutics, Inc. (DFTX), though the article notes the effectiveness of such targets is questionable. The piece suggests a positive trend in earnings estimate revisions could lead to upside.

Why it matters — DFTX watchers would care because the article highlights both a consensus analyst price target indicating significant upside and recent positive earnings estimate revisions, two factors often considered when evaluating a stock's outlook.

Definium Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026

Business Wire · 30 July 2026neutral

Definium Therapeutics announced it will host a webcast on August 6, 2026, to report its second quarter 2026 financial results and discuss recent business highlights.

Why it matters — Shareholders and analysts will gain insight into the company's financial performance and operational progress for the second quarter.

FAQ

Frequently asked questions about DFTX stock

What is the DFTX stock price forecast for 2026-2027?

The 16 Wall Street analysts covering Definium Therapeutics, Inc. have a median 12-month price target of $59, with estimates ranging from $50 to $74. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is DFTX stock a buy right now?

Of the 16 analysts covering Definium Therapeutics, Inc., 16 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Definium Therapeutics, Inc. 38 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank DFTX?

As at 1 Aug 2026, Definium Therapeutics, Inc. ranks 38 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (100 of 100).

Will DFTX stock go up?

No one can know that. What the data says: the median 12-month target from 16 analysts implies +41.2% from the last close, and Ticker Nerd's factor model ranks Definium Therapeutics, Inc. 38 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the DFTX stock forecast for 2030?

No analyst covering Definium Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DFTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $50 to $74 over the next 12 months.

How has DFTX stock performed over the past year?

Definium Therapeutics, Inc. returned +395.1% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Definium Therapeutics, Inc. do?

Definium Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for psychiatric and neurological disorders.

What is the latest news on DFTX?

The most recent item we track (Zacks Investment Research, 31 July 2026): "Wall Street Analysts See a 34.86% Upside in Definium Therapeutics, Inc. (DFTX): Can the Stock Really Move This High?". Zacks Investment Research reported that the average of Wall Street analysts' price targets implies a potential 34.9% upside in Definium Therapeutics, Inc. (DFTX), though the article notes the effectiveness of such targets is questionable. The piece suggests a positive trend in earnings estimate revisions could lead to upside.

Company

About Definium Therapeutics, Inc.

Definium Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for psychiatric and neurological disorders. Headquartered in New York City, the company applies scientific rigor to psychedelic-based medicine to address underlying disease mechanisms rather than temporary symptom relief. Definium’s lead program centers on DT120, an orally disintegrating tablet formulation of lysergide (LSD) being evaluated in late-stage clinical trials for major depressive disorder and generalized anxiety disorder, where it has received FDA Breakthrough Therapy Designation for GAD. The company is also advancing DT402, the R-enantiomer of MDMA, targeting core symptoms of autism spectrum disorder, particularly social communication challenges. Operating within the pharmaceuticals and biotechnology sectors, Definium Therapeutics occupies a specialized position in the emerging field of evidence-based psychedelic therapeutics, aiming to provide accessible, scalable treatment options across high-burden mental health and brain health indications.

CEO Mr. Robert Barrow · 105 employees · United States · https://definiumtx.com